Liver Disease Clinical Trials in San Antonio, Texas

12 recruitingSan Antonio, Texas

Showing 112 of 12 trials

Recruiting
Phase 1

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Liver DiseasesHepatic Insufficiency
Incyte Corporation16 enrolled4 locationsNCT07559474
Recruiting
Phase 1

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline32 enrolled3 locationsNCT07358546
Recruiting
Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled349 locationsNCT06318169
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Phase 3

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,200 enrolled49 locationsNCT07221227
Recruiting
Phase 3

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Non-Alcoholic Fatty Liver Disease
GlaxoSmithKline1,250 enrolled43 locationsNCT07221188
Recruiting
Phase 2

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

Liver Diseases, Alcoholic
GlaxoSmithKline393 enrolled131 locationsNCT06613698
Recruiting
Phase 2

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Alcohol Liver Disease
Altimmune, Inc.100 enrolled43 locationsNCT07009860
Recruiting
Phase 4

Quantifying Hepatic Mitochondrial Fluxes in Humans

Non-Alcoholic Fatty Liver DiseaseType 2 DiabetesMitochondrial Metabolism Disorders
The University of Texas Health Science Center at San Antonio60 enrolled2 locationsNCT05305287
Recruiting

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Pediatric ALLMalnutritionParenteral Nutrition Associated Liver Disease (PNALD)+1 more
Fresenius Kabi40 enrolled10 locationsNCT06274788
Recruiting

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Cirrhosis, LiverLiver FibrosisLiver Steatoses+5 more
Foundation for the National Institutes of Health400 enrolled4 locationsNCT07122700